Details of the Drug

General Information of Drug (ID: DMAP58Y)

Drug Name
Peginterferon alfa-2b
Synonyms PegIntron; Peginterferon alfa-2b (INN); Peginterferon alfa-2b (generical recombination); Peginterferon alfa-2b (generical recombination) (JAN)
Indication
Disease Entry ICD 11 Status REF
Hepatitis C virus infection 1E51.1 Approved [1]
Leukemia N.A. Approved [2]
Liver cirrhosis DB93.1 Approved [3]
Therapeutic Class
Antiviral Agents
Affected Organisms
Humans and other mammals
ATC Code
L03AB10: Peginterferon alfa-2b
L03AB: Interferons
L03A: IMMUNOSTIMULANTS
L03: IMMUNOSTIMULANTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Sequence
CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMI
QQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVR
KYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE
ADMET Property
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 10-15 mcg/L []
Bioavailability
The bioavailability of drug is 100% []
Elimination
Renal elimination accounts for 30% of Peginterferon alfa-2b elimination []
Half-life
The concentration or amount of drug in body reduced by one-half in 2b is 40 hours []
Adverse Drug Reaction (ADR)
ADR Term Variation Related DOT DOT ID REF
Gastrointestinal disorders Not Available OXTR OT7WFW4U [4]
Cross-matching ID
UNII
G8RGG88B68
DrugBank ID
DB00022
TTD ID
D08NWC
VARIDT ID
DR00418
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interferon-alpha 2 (IFNA2) TTSIUJ9 IFNA2_HUMAN Modulator [5]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Interferon lambda-3 (IFNL3) OTPIMGAU IFNL3_HUMAN Drug Response [6]
Oxytocin receptor (OXTR) OT7WFW4U OXYR_HUMAN Drug Response [4]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Hepatitis C virus infection
ICD Disease Classification 1E51.1
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interferon-alpha 2 (IFNA2) DTT IFNA2 9.31E-04 0.35 2.05
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Peginterferon alfa-2b (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Peginterferon alfa-2b and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [7]
Thioguanine DM7NKEV Moderate Increased risk of hepatotoxicity by the combination of Peginterferon alfa-2b and Thioguanine. Acute myeloid leukaemia [2A60] [8]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Peginterferon alfa-2b and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [9]
Aminophylline DML2NIB Moderate Decreased metabolism of Peginterferon alfa-2b caused by Aminophylline mediated inhibition of CYP450 enzyme. Asthma [CA23] [7]
Roflumilast DMPGHY8 Moderate Additive immunosuppressive effects by the combination of Peginterferon alfa-2b and Roflumilast. Asthma [CA23] [10]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Peginterferon alfa-2b and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [11]
Oxtriphylline DMLHSE3 Moderate Decreased metabolism of Peginterferon alfa-2b caused by Oxtriphylline mediated inhibition of CYP450 enzyme. Cough [MD12] [7]
PMID27977313-Compound-29 DMIF7KG Moderate Increased risk of hepatotoxicity by the combination of Peginterferon alfa-2b and PMID27977313-Compound-29. Discovery agent [N.A.] [12]
PMID28870136-Compound-48 DMPIM9L Moderate Decreased metabolism of Peginterferon alfa-2b caused by PMID28870136-Compound-48 mediated inhibition of CYP450 enzyme. Discovery agent [N.A.] [7]
Stiripentol DMMSDOY Moderate Decreased metabolism of Peginterferon alfa-2b caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [10]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Peginterferon alfa-2b and Cannabidiol. Epileptic encephalopathy [8A62] [10]
Brentuximab vedotin DMWLC57 Moderate Increased risk of peripheral neuropathy by the combination of Peginterferon alfa-2b and Brentuximab vedotin. Hodgkin lymphoma [2B30] [13]
Efavirenz DMC0GSJ Moderate Increased risk of hepatotoxicity by the combination of Peginterferon alfa-2b and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [14]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Peginterferon alfa-2b and Mipomersen. Hyper-lipoproteinaemia [5C80] [15]
Teriflunomide DMQ2FKJ Major Additive immunosuppressive effects by the combination of Peginterferon alfa-2b and Teriflunomide. Hyper-lipoproteinaemia [5C80] [16]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Peginterferon alfa-2b and BMS-201038. Hyper-lipoproteinaemia [5C80] [17]
Ramelteon DM7IW9J Moderate Decreased metabolism of Peginterferon alfa-2b caused by Ramelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [18]
Polyethylene glycol DM4I1JP Moderate Increased risk of lowers seizure threshold by the combination of Peginterferon alfa-2b and Polyethylene glycol. Irritable bowel syndrome [DD91] [19]
Methotrexate DM2TEOL Moderate Increased risk of hepatotoxicity by the combination of Peginterferon alfa-2b and Methotrexate. Leukaemia [2A60-2B33] [10]
Denosumab DMNI0KO Moderate Additive immunosuppressive effects by the combination of Peginterferon alfa-2b and Denosumab. Low bone mass disorder [FB83] [20]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Peginterferon alfa-2b and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [12]
Cladribine DM3JDRP Major Additive immunosuppressive effects by the combination of Peginterferon alfa-2b and Cladribine. Mature B-cell leukaemia [2A82] [10]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Peginterferon alfa-2b and Idelalisib. Mature B-cell leukaemia [2A82] [21]
Alemtuzumab DMZL3IV Moderate Additive immunosuppressive effects by the combination of Peginterferon alfa-2b and Alemtuzumab. Mature B-cell leukaemia [2A82] [22]
Clofarabine DMCVJ86 Moderate Increased risk of hepatotoxicity by the combination of Peginterferon alfa-2b and Clofarabine. Mature B-cell lymphoma [2A85] [23]
Thalidomide DM70BU5 Moderate Increased risk of peripheral neuropathy by the combination of Peginterferon alfa-2b and Thalidomide. Multiple myeloma [2A83] [24]
Bortezomib DMNO38U Moderate Increased risk of peripheral neuropathy by the combination of Peginterferon alfa-2b and Bortezomib. Multiple myeloma [2A83] [24]
Interferon beta-1a DM1A6RV Moderate Increased risk of hepatotoxicity by the combination of Peginterferon alfa-2b and Interferon beta-1a. Multiple sclerosis [8A40] [25]
Tecfidera DM2OVDT Moderate Additive immunosuppressive effects by the combination of Peginterferon alfa-2b and Tecfidera. Multiple sclerosis [8A40] [26]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Peginterferon alfa-2b and Siponimod. Multiple sclerosis [8A40] [7]
Fingolimod DM5JVAN Major Additive immunosuppressive effects by the combination of Peginterferon alfa-2b and Fingolimod. Multiple sclerosis [8A40] [27]
Interferon beta-1b DMCN61Z Moderate Increased risk of hepatotoxicity by the combination of Peginterferon alfa-2b and Interferon beta-1b. Multiple sclerosis [8A40] [25]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Peginterferon alfa-2b and Ozanimod. Multiple sclerosis [8A40] [10]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive immunosuppressive effects by the combination of Peginterferon alfa-2b and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [28]
Bupropion DM5PCS7 Major Increased risk of lowers seizure threshold by the combination of Peginterferon alfa-2b and Bupropion. Nicotine use disorder [6C4A] [29]
Tramadol DMRQD04 Major Increased risk of lowers seizure threshold by the combination of Peginterferon alfa-2b and Tramadol. Pain [MG30-MG3Z] [30]
Rasagiline DM3WKQ4 Moderate Decreased metabolism of Peginterferon alfa-2b caused by Rasagiline mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [7]
Ropinirole DMA6S1D Moderate Decreased metabolism of Peginterferon alfa-2b caused by Ropinirole mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [31]
Lindane DMB8CNL Moderate Increased risk of lowers seizure threshold by the combination of Peginterferon alfa-2b and Lindane. Pediculosis [1G00] [32]
Leflunomide DMR8ONJ Major Increased risk of hepatotoxicity by the combination of Peginterferon alfa-2b and Leflunomide. Rheumatoid arthritis [FA20] [16]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Peginterferon alfa-2b and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [10]
Epirubicin DMPDW6T Moderate Increased risk of hepatotoxicity by the combination of Peginterferon alfa-2b and Epirubicin. Solid tumour/cancer [2A00-2F9Z] [7]
Pitolisant DM8RFNJ Moderate Decreased metabolism of Peginterferon alfa-2b caused by Pitolisant mediated inhibition of CYP450 enzyme. Somnolence [MG42] [10]
Tizanidine DMR2IQ4 Major Decreased metabolism of Peginterferon alfa-2b caused by Tizanidine mediated inhibition of CYP450 enzyme. Tonus and reflex abnormality [MB47] [33]
Ganciclovir DM1MBYQ Moderate Additive myelosuppressive effects by the combination of Peginterferon alfa-2b and Ganciclovir. Virus infection [1A24-1D9Z] [7]
Valganciclovir DMS2IUH Moderate Additive myelosuppressive effects by the combination of Peginterferon alfa-2b and Valganciclovir. Virus infection [1A24-1D9Z] [7]
⏷ Show the Full List of 46 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7462).
2 Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol. 2020 Mar;7(3):e196-e208.
3 Hepatitis B therapy. Nat Rev Gastroenterol Hepatol. 2011 May;8(5):275-84.
4 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
6 Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon--based regimens. Clin Pharmacol Ther. 2014 Feb;95(2):141-6. doi: 10.1038/clpt.2013.203. Epub 2013 Oct 4.
7 Cerner Multum, Inc. "Australian Product Information.".
8 Product Information. Aubagio (teriflunomide). Genzyme Corporation, Cambridge, MA.
9 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
10 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
11 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
12 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
13 Product Information. Accolate (zafirlukast). Zeneca Pharmaceuticals, Wilmington, DE.
14 Elsharkawy AM, Schwab U, McCarron B, et al. "Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser." J Clin Virol 58 (2013): 331-3. [PMID: 23763943]
15 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
16 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
17 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
18 Product Information. Rozerem (ramelteon). Takeda Pharmaceuticals America, Lincolnshire, IL.
19 Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
20 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
21 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
22 Product Information. Campath (alemtuzumab) Berlex, Richmond, CA.
23 Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
24 Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6. [PMID: 219931]
25 Product Information. Avonex (interferon beta-1a). Biogen, Cambridge, MA.
26 Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
27 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
28 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
29 Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.
30 Product Information. Ultram (tramadol). McNeil Pharmaceutical, Raritan, NJ.
31 Product Information. Noroxin (norfloxacin). Merck & Co, Inc, West Point, PA.
32 Matsuoka LY "Convulsions following application of gamma benzene hexachloride." J Am Acad Dermatol 5 (1981): 98-9. [PMID: 6168673]
33 Granfors MT, Backman JT, Laitila J, Neuvonen PJ "Tizanidine is mainly metabolized by cytochrome P450 1A2 in vitro." Br J Clin Pharmacol 57 (2004): 349-53. [PMID: 14998432]